JP2023529570A5 - - Google Patents

Info

Publication number
JP2023529570A5
JP2023529570A5 JP2022571212A JP2022571212A JP2023529570A5 JP 2023529570 A5 JP2023529570 A5 JP 2023529570A5 JP 2022571212 A JP2022571212 A JP 2022571212A JP 2022571212 A JP2022571212 A JP 2022571212A JP 2023529570 A5 JP2023529570 A5 JP 2023529570A5
Authority
JP
Japan
Prior art keywords
cyano
disease
tautomer
deficiency
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022571212A
Other languages
English (en)
Japanese (ja)
Other versions
JP7796047B2 (ja
JP2023529570A (ja
Filing date
Publication date
Priority claimed from GBGB2008401.8A external-priority patent/GB202008401D0/en
Priority claimed from GBGB2016689.8A external-priority patent/GB202016689D0/en
Priority claimed from GBGB2101935.1A external-priority patent/GB202101935D0/en
Application filed filed Critical
Priority claimed from PCT/EP2021/064897 external-priority patent/WO2021245186A1/en
Publication of JP2023529570A publication Critical patent/JP2023529570A/ja
Publication of JP2023529570A5 publication Critical patent/JP2023529570A5/ja
Application granted granted Critical
Publication of JP7796047B2 publication Critical patent/JP7796047B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022571212A 2020-06-04 2021-06-03 Ｕｓｐ３０阻害剤としての活性を有するｎ－シアノピロリジン Active JP7796047B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB2008401.8 2020-06-04
GBGB2008401.8A GB202008401D0 (en) 2020-06-04 2020-06-04 Novel compounds
GB2016689.8 2020-10-21
GBGB2016689.8A GB202016689D0 (en) 2020-10-21 2020-10-21 Novel compounds
GBGB2101935.1A GB202101935D0 (en) 2021-02-11 2021-02-11 Novel compounds
GB2101935.1 2021-02-11
PCT/EP2021/064897 WO2021245186A1 (en) 2020-06-04 2021-06-03 N-cyanopyrrolidines with activity as usp30 inhibitors

Publications (3)

Publication Number Publication Date
JP2023529570A JP2023529570A (ja) 2023-07-11
JP2023529570A5 true JP2023529570A5 (enExample) 2025-10-30
JP7796047B2 JP7796047B2 (ja) 2026-01-08

Family

ID=76421953

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022571212A Active JP7796047B2 (ja) 2020-06-04 2021-06-03 Ｕｓｐ３０阻害剤としての活性を有するｎ－シアノピロリジン

Country Status (13)

Country Link
US (1) US12679833B2 (enExample)
EP (1) EP4161920A1 (enExample)
JP (1) JP7796047B2 (enExample)
KR (1) KR20230019198A (enExample)
CN (1) CN115698001A (enExample)
AU (1) AU2021285130A1 (enExample)
BR (1) BR112022019722A2 (enExample)
CA (1) CA3185654A1 (enExample)
CO (1) CO2022017112A2 (enExample)
IL (1) IL298710A (enExample)
MX (1) MX2022015254A (enExample)
WO (1) WO2021245186A1 (enExample)
ZA (1) ZA202213866B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS67140B1 (sr) 2020-06-08 2025-09-30 Mission Therapeutics Ltd 1-(5-(2-cijanopiridin-4-il)oksazol-2-karbonil)-4-metilheksahidropirolo[3,4-b]pirol-5(1h)-karbonitril kao usp30 inhibitor za primenu u lečenju mitohondrijske disfunkcije, kancera i fibroze
WO2023099561A1 (en) 2021-12-01 2023-06-08 Mission Therapeutics Limited Substituted n-cyanopyrrolidines with activity as usp30 inhibitors
EP4547247A4 (en) * 2022-06-30 2026-08-12 Dana Farber Cancer Inst Inc DESUBIQUITINASE INHIBITORS AND THEIR METHODS OF USE
GB202408928D0 (en) 2024-06-21 2024-08-07 Mission Therapeutics Ltd Novel compounds
GB202411060D0 (en) 2024-07-29 2024-09-11 Mission Therapeutics Ltd Novel compounds
CN119528901B (zh) * 2024-11-05 2026-05-26 上海市同济医院 噻唑类化合物、去sumo和/或去泛素化酶抑制剂及其制备方法和应用
GB202500610D0 (en) 2025-01-16 2025-03-05 Mission Therapeutics Ltd Novel compounds

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665754A (en) 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
US6187797B1 (en) 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
JP2003530384A (ja) 2000-04-06 2003-10-14 メルク フロスト カナダ アンド カンパニー カテプシンシステインプロテアーゼ阻害薬
AU2003263393A1 (en) 2002-09-04 2004-03-29 Glenmark Pharmaceuticals Limited New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2007119214A2 (en) 2006-04-13 2007-10-25 Actelion Pharmaceuticals Ltd Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
US8242271B2 (en) 2007-06-04 2012-08-14 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
US20090264431A1 (en) 2007-08-20 2009-10-22 Palovich Michael R Novel cathepsin c inhibitors and their use
WO2009129370A1 (en) 2008-04-18 2009-10-22 Glaxo Group Limited Cathepsin c inhibitors
UY31770A1 (es) 2008-04-18 2009-09-30 Inhibidores de catepsina c
UY31771A1 (es) 2008-04-18 2009-09-30 Inhibidores de catepsina c
UA105005C2 (uk) 2008-06-16 2014-04-10 Юніверсіті Оф Теннессі Рісерч Фаундейшн Сполуки для лікування раку
CA2741666C (en) 2008-10-31 2017-04-11 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
US8946231B2 (en) 2009-03-23 2015-02-03 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
JP5852658B2 (ja) 2010-09-24 2016-02-03 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン デユビキチナーゼ阻害剤およびその使用方法
US20120309820A1 (en) 2011-06-04 2012-12-06 Jb Therapeutics Inc. Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
EP2565186A1 (en) 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
KR102438072B1 (ko) 2012-01-12 2022-08-31 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
TW201524952A (zh) 2013-03-15 2015-07-01 Araxes Pharma Llc Ｋｒａｓ ｇ１２ｃ之共價抑制劑
JP6612751B2 (ja) 2013-07-31 2019-11-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｔｋの阻害剤としてのピリジン、ピリミジン及びピラジンならびにその使用
US9963444B2 (en) 2014-05-19 2018-05-08 Northeastern University N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and their use thereof
US20170095457A1 (en) 2014-05-27 2017-04-06 David Lonergan Compositions and methods of delivery of deubiquitinase inhibitors
WO2016019237A2 (en) 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
WO2016021629A1 (ja) 2014-08-06 2016-02-11 塩野義製薬株式会社 ＴｒｋＡ阻害活性を有する複素環および炭素環誘導体
GB201416754D0 (en) * 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
LT3277677T (lt) 2015-03-30 2021-05-25 Mission Therapeutics Limited 1-ciano-pirolidino junginiai kaip usp30 inhibitoriai
EP3322702B1 (en) 2015-07-14 2019-11-20 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
GB201521109D0 (en) 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522267D0 (en) * 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
MA43753A (fr) 2016-03-24 2018-11-28 Mission Therapeutics Ltd Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu
ES2850349T3 (es) 2016-09-27 2021-08-27 Mission Therapeutics Ltd Derivados de cianopirrolidina con actividad como inhibidores de USP30
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
US10968172B2 (en) 2017-05-15 2021-04-06 Mitobridge, Inc. USP30 inhibitors
GB201708652D0 (en) 2017-05-31 2017-07-12 Mission Therapeutics Ltd Novel compounds and uses
GB2563595B (en) 2017-06-19 2020-04-15 Edwards Ltd Twin-shaft pumps
JP7208931B2 (ja) 2017-06-20 2023-01-19 ミッション セラピューティクス リミティド Ｄｕｂ阻害剤としての活性をもつ置換シアノピロリジン類
AU2018346597B2 (en) 2017-10-06 2023-07-13 Forma Therapeutics, Inc. Inhibiting Ubiquitin Specific Peptidase 30
GB2571731A (en) 2018-03-06 2019-09-11 Mission Therapeutics Ltd Novel compounds and uses
IL278291B2 (en) 2018-05-17 2023-10-01 Forma Therapeutics Inc Condensed bicyclic compounds are useful as ubiquitin-specific peptidase 30 inhibitors
EP3837262B1 (en) 2018-08-14 2026-06-17 Amgen Inc. N-cyano-7-azanorbornane derivatives and uses thereof
EP4218934B1 (en) 2018-10-05 2025-06-18 Forma Therapeutics, Inc. Inhibiting ubiquitin-specific protease 30 (usp30)
GB201905371D0 (en) * 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201912674D0 (en) 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds
MX2022012578A (es) 2020-04-08 2022-11-07 Mission Therapeutics Ltd N-cianopirrolidinas con actividad como inhibidores de usp30.
KR20230016674A (ko) 2020-05-28 2023-02-02 미션 테라퓨틱스 엘티디 미토콘드리아 기능장애의 치료를 위한 usp30 억제제로서 n-(1-시아노피롤리딘-3-일)-5-(3-(트라이플루오로메틸)페닐)옥사졸-2-카복스아미드 유도체 및 상응하는 옥사다이아졸 유도체
RS67140B1 (sr) 2020-06-08 2025-09-30 Mission Therapeutics Ltd 1-(5-(2-cijanopiridin-4-il)oksazol-2-karbonil)-4-metilheksahidropirolo[3,4-b]pirol-5(1h)-karbonitril kao usp30 inhibitor za primenu u lečenju mitohondrijske disfunkcije, kancera i fibroze

Similar Documents

Publication Publication Date Title
JP2022546717A5 (enExample)
JP6959332B2 (ja) Ｕｓｐ３０の阻害剤としての活性を有するシアノピロリジン誘導体
AP813A (en) Urea derivatives as inhibitors of IMPDH enzyme.
JP2023528087A5 (enExample)
AU2011210567B2 (en) Small molecules for the modulation of MCL-1 and methods of modulatiing cell death, cell division, cell differentiation and methods of treating disorders
JP2020189882A (ja) Ｍｅｋインヒビターおよびその使用方法
JP2019501142A5 (enExample)
CN104334556B (zh) 新型1‑磷酸鞘氨醇受体拮抗剂
AU2017254523A1 (en) Compounds and compositions for treating conditions associated with NLRP activity
JP2019503362A5 (enExample)
JP2020512298A5 (enExample)
KR20150000866A (ko) 글루타미나제의 헤테로사이클릭 억제제
JP7796047B2 (ja) Ｕｓｐ３０阻害剤としての活性を有するｎ－シアノピロリジン
JP2013531029A (ja) 化合物
JP2015503527A5 (enExample)
WO2010115836A4 (en) Substituted piperidines as ccr3 antagonists
HRP20250891T1 (hr) 1-(5-(2-cijanopiridin-4-il)oksazol-2-karbonil)-4-metilheksahidropirolo[3,4-b]pirol-5(1h)-karbonitril kao usp30 inhibitor za primjenu u liječenju mitohondrijske disfunkcije, raka i fibroze
JP2020143129A5 (enExample)
KR20230006487A (ko) Usp30 억제제로서의 활성을 갖는 n-시아노피롤리딘
TW202313050A (zh) 組合療法
JP2024544660A5 (enExample)
JP2014144916A (ja) ２−アシルアミノチアゾール化合物の結晶
JP2024544660A (ja) Ｕｓｐ３０阻害剤としての活性を有する置換ｎ－シアノピロリジン
JP2009523842A (ja) ナトリウムチャネルモジュレーターとしてのピリジン誘導体
JP2021510168A5 (enExample)